In particular, I explore pharmacological targeting and characterization of upstream-driven feedbacks of MAPK pathway. I study and characterize the response to KRAS G12C, SOS1 and SHP2 inhibitors alone ...

The BRAFV600 mutation is found in about 50% of melanomas, and patients whose tumors harbor this mutation are often treated with MAPK inhibitors, which target the tumor's growth pathway.

This helps the tumour create alternative versions of the protein (altBRAFs) which lack regions targeted by BRAF inhibitors, reactivating the MAPK pathway and making the drugs less effective.

Pasithea Therapeutics reports encouraging early Phase 1 data for PAS-004, showing no adverse events or toxicities. The trial ...

(Nasdaq: ERAS), a clinical-stage precision oncology company singularly f Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor for multiple RAS/MAPK pathway-driven tumors ...

which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio ...

Historically, most people started HIV treatment with two drugs from the NRTI class combined with either one NNRTI, one protease inhibitor or one integrase inhibitor – hence, ‘triple therapy’.

China-ASEAN Belt and Road Joint Laboratory on Mariculture Technology, Guangzhou, China ...

Join Labroots for the highly anticipated 12th Annual Cancer Research & Oncology Virtual Event Series on October 2nd, 2024. This event will unite esteemed academic and industry experts and medical ...